trial

IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

NCTId NCT03194815
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Active Not Recruiting
Enrollment 70 (estimated)
Sponsored by University of Cambridge
Primary completion 2027-04-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Active Not Recruiting
Enrollment
70 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-11-01
Primary completion
2027-04-30
Eligibility
ALL · 16 Years · 70 Years

Interventions & indications

Drugs
Intravenous immunoglobulinRituximab

Sponsors

University of CambridgeLead Sponsor
University of OxfordCollaborator

Investigators

1
Alasdair Coles, PhD FRCPPrincipal Investigator

Sites

10 total
Cambridge, United KingdomExeter, United KingdomGlasgow, United KingdomLiverpool, United KingdomLondon, United KingdomLondon, United KingdomManchester, United KingdomNottingham, United KingdomOxford, United KingdomSheffield, United Kingdom

Linked catalysts

1
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 — primary completion2027-04-30

Facts & assertions

4 sourced
Enrollment
70
Phase
PHASE2
Primary Completion Date
2027-04-30
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
Intravenous immunoglobulin
drug
Rituximab
drug
lead_sponsor
University of Cambridge
company
collaborator
University of Oxford
company
indication
Autoimmune Encephalitis
indication
Psychosis
indication
Autoimmune Diseases of the Nervous System
indication
investigator
Alasdair Coles, PhD FRCP
person